Skip to main content

Table 2 Patient demographics and baseline characteristics between group A and group C and between group B and group D

From: Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

Factors > 4 weeks ≤ 4 weeks
Group A Group C P value Group B Group D P value
Sex (M/F) 34/3 23/5 0.275 22/5 26/5 1.000
Age (years) 40 (35–46.5) 47.5 (37.5–56.5) 0.035 42 (33–50) 44 (35–60) 0.435
ALT (U/L) 88 (46.5–312) 48 (23.25–75.75) 0.004 77 (46–336) 42.5 (25.25–89) 0.005
AST (U/L) 109 (68–173.5) 73 (45.25–131.5) 0.054 103 (68–147) 65 (47.5–92) 0.002
TBIL (mmol/L) 486 (346–550.5) 415 (85.25–488.5) 0.043 381 (219–495) 149 (75.75–306.75) 0.000
PTA 35 (25.5–40.5) 40.5 (29.75–53) 0.033 34 (31–47) 44.5 (34.75–59.25) 0.006
MELD 78 (76.5–81) 76 (73–78) 0.006 77 (75–82) 72 (67.75–76) 0.000
  1. ALT alanine aminotransferase, AST glutamic-oxaloacetic transaminase, TBIL total bilirubin, PTA prothrombin time activity, MELD model for end-stage liver disease